Vilobelimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric |
| Target | Complement component 5a (C5a) |
| Clinical data | |
| Trade names | Gohibic |
| Other names | IFX-1 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6456H9976N1716O2054S44 |
| Molar mass | 145907.42 g·mol−1 |
Vilobelimab, sold under the brand name Gohibic, is a monoclonal antibody that is used for the treatment of COVID-19.[1][2][4] It is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma.[5]
The most common adverse reactions include pneumonia, sepsis, delirium, pulmonary embolism, hypertension, pneumothorax, deep vein thrombosis, herpes simplex, enterococcal infection, bronchopulmonary aspergillosis, hepatic enzyme increased, urinary tract infection, hypoxia, thrombocytopenia, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash.[4]
Vilobelimab is a recombinant chimeric monoclonal IgG4 antibody that specifically binds to the soluble human complement split product C5a after cleavage from C5 to block its interaction with the C5a receptor, both of which are components of the complement system thought to contribute to inflammation and worsening of COVID-19.[6] Vilobelimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in April 2023.[4][6][5][7][8] Vilobelimab was authorized for medical use in the European Union in January 2025.[2][3]
- ^ a b "Gohibic- vilobelimab injection". DailyMed. 16 May 2023. Retrieved 16 January 2025.
- ^ a b c "Gohibic EPAR". European Medicines Agency (EMA). 14 November 2024. Retrieved 16 November 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Gohibic PI". Union Register of medicinal products. 14 January 2025. Retrieved 16 January 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c "FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 4 April 2023. Retrieved 4 April 2023. This article incorporates text from this source, which is in the public domain.
- ^ a b fda.gov
- ^ a b fda.gov This article incorporates text from this source, which is in the public domain.
- ^ fda.gov
- ^ "InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients" (Press release). InflaRx N.V. 4 April 2023. Retrieved 4 April 2023 – via GlobeNewswire.